NEW YORK (GenomeWeb) – A new study this week by Trovagene and its academic collaborators is the first to demonstrate the validity of the company's liquid biopsy strategy for detecting EGFR mutations in both blood and urine of patients with lung cancer.
The paper, published online in the Journal of Thoracic Oncology this week, is an important step for Trovagene toward broadening adoption if its tests beyond what is currently a relatively small corps of early adopters, company officials told GenomeWeb.